UK-based synthetic biology company Prokarium raised $10m in a series B round yesterday led by Riyadh Valley Company, the venture capital arm of King Saud University.
The round also included venture capital firms Flerie Invest and Korea Investment Partners.
Founded in 2007, Prokarium has developed a vaccine delivery platform called Vaxonella. Patients swallow a product containing microbes that produce vaccines from within the body’s own immune cells, offering minimal side effects and being more cost efficient than injections.
The approach…
